Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00442871

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Purpura, Thrombocytopaenic, Idiopathic Clinical Trial

Official title:
An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg Eltrombopag in Healthy Subjects and in Subjects With Mild, Moderate, or Severe Renal Impairment

Clinical Trial Summary

The main purpose of this study is to compare how one 50 mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe kidney problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00442871
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date September 28, 2006
Completion date January 3, 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT00908037 - Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT01098487 - A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Phase 4
Withdrawn NCT01440361 - A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. Phase 2
Completed NCT01064336 - Promacta Pregnancy Registry N/A
Completed NCT00424177 - Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) Phase 2
Completed NCT00351468 - EXTEND (Eltrombopag Extended Dosing Study) Phase 3
Completed NCT00688272 - Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag Phase 1
Completed NCT01072162 - Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect Phase 1
Completed NCT00643929 - LENS - Long-term Eltrombopag Observational Study N/A
Completed NCT00102739 - SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT01416311 - Drug Use Investigation for REVOLADE (ITP)
Completed NCT00359463 - Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment Phase 1